CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 179 filers reported holding CRISPR THERAPEUTICS AG in Q2 2018. The put-call ratio across all filers is 3.04 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $510,000 | -27.6% | 3,334 | -60.4% | 0.00% | -33.3% |
| Q3 2020 | $704,000 | +13.7% | 8,423 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $619,000 | +79.9% | 8,423 | +3.9% | 0.00% | +50.0% |
| Q1 2020 | $344,000 | -30.4% | 8,109 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $494,000 | +48.8% | 8,109 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $332,000 | -14.2% | 8,109 | -1.2% | 0.00% | 0.0% |
| Q2 2019 | $387,000 | +31.6% | 8,209 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $294,000 | +12.6% | 8,209 | +84.9% | 0.00% | +100.0% |
| Q2 2018 | $261,000 | +29.2% | 4,440 | +0.2% | 0.00% | 0.0% |
| Q1 2018 | $202,000 | – | 4,430 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |